Dermatology

Pharma

Novartis expands Rhapsido's growing reach in chronic hives

After a first approval in chronic hives, Novartis’ Rhapsido is expanding its reach with a new FDA nod that comes with a notable ‘first’ for the field.

Fraiser Kansteiner Oct 7, 2026 2:27pm

Two hands with vitiligo holding each other

Litfulo and tilrekimig data bolster Pfizer's immunology plans

Oct 2, 2026 11:15am

Organon phones home with sci-fi themed Vtama campaign

Sep 30, 2026 4:36pm

hair hair loss baldness female pattern hair loss

Veradermics reports ph. 2 win in female pattern hair loss

Jul 15, 2026 11:27am

Skin quality driving widespread quality-of-life issues: survey

Jul 7, 2026 4:47am

Medical terminology and medicine paperwork writing tiny neubrutalism concept

A patient-first shift in disease language and communication

Jun 3, 2026 11:35am